One of the Board’s basic responsibilities is to set our strategy and monitor progress towards meeting our objectives, 这样澳门第一赌城在线娱乐才能把科学带给病人, 为社会创造价值, 并奖励你, 澳门第一赌城在线娱乐的股东.
2017年对澳门在线赌城娱乐来说是决定性的一年. 2018 will be equally important as we seek to deliver the full potential of our medicines and ensure we deliver our science to patients around the world.
In 2017, our financial performance reflected the launch of several new medicines, the strong performance of our Growth Platforms and the continued impact from patent expiries; most notably for Crestor and Seroquel XR in the US.
主要亮点
总营收
$22.5bn
经营活动产生的现金流量净额
$3.6bn
报告营业利润
$3.7bn
核心营业利润
$6.9bn
报告每股收益
$2.37
Core EPS
$4.28
At a Glance
We are a global biopharmaceutical business delivering medicines to patients through innovative science and excellence in development and commercialisation.
产品销售
$20,152m
2016: $21,319m
2015: $23,641m
按治疗区域划分
-01.png/jcr:content/renditions/cq5dam.web.320.AZ_Portfolio_of_specialty_and_primary_care_products_(product_sales)-01.png)
通过地理
-01.png/jcr:content/renditions/cq5dam.web.320.AZ_Global_commercial_presence_with_strength_in_Emerging_Markets_(product_sales)-01.png)
61,100
100%
84%
普通股股息
for 2017
第一次中期股息
$0.90
Pence: 68.9
SEK: 7.40
付款日期:2017年9月11日
第二次中期股息
$1.90
Pence: 133.6
SEK: 14.97
付款日期:2018年3月19日
Total
$2.80
Pence: 202.5
SEK: 22.37
Strategy
We announced our strategy for returning to growth in 2013. We moved on from the first phase in our journey, focused on rebuilding our pipeline, in 2015. The second stage is crucial as we drive our Growth Platforms forward, continue to launch new medicines and make them available to patients. 展望2020年及以后, continued investment in our pipeline will keep us on track to return to sustainable growth in line with our targets.
In 2017, our strategic priorities were focused under the three pillars described below.
-
实现科学领导
We are focusing our science on three therapy areas and accelerating our pipeline. 澳门第一赌城在线娱乐也在改变澳门第一赌城在线娱乐的工作方式.
-
回归增长
We are focusing on our Growth Platforms and transforming the business through specialty care, 器械和生物药品. Targeted business development reinforces our efforts.
-
成为一个伟大的工作场所
We are evolving our culture and simplifying our business. 澳门第一赌城在线娱乐希望吸引并留住最优秀的人才. 澳门第一赌城在线娱乐也希望以可持续的方式开展业务.
治疗领域亮点
We have transformed our drugs portfolio by focusing on three therapy areas: Oncology, 心血管 & 代谢疾病 (CVMD) and Respiratory, while being selectively active in 其他疾病领域.
Oncology
$4,024m
产品销售额(2016年:33.83亿美元，2015年:28.25亿美元)
Highlights
- Tagrisso sales up 126% (126% at CER) and approved in more than 60 markets
- Iressa 销售额5.28亿美元，增长3%(按CER计算为3%); Lynparza 销售额2.97亿美元，增长36%(按CER计算增长35%)。
- Imfinzi launched in the US in May and sales of $19 million; Calquence launched in the US in October and sales of $3 million
心血管 & 代谢疾病
$7,266m
产品销售额(2016:81.16亿美元，2015:94.89亿美元)
Highlights
- Brilinta sales of $1,079 million, up 29% (29% at CER) and Forxiga 销售额10.74亿美元，增长29%(按CER计算增长28%)。
- Sales of Onglyza 下降了15%(按CER计算为16%)，至6.11亿美元
- 传统销售: Crestor 下跌30%(按CER计算为30%)，至23.65亿美元
Respiratory
$4,706m
产品销售额(2016年:47.53亿美元，2015年:49.87亿美元)
Highlights
- Symbicort 销售额28.03亿美元，下降6%(按CER计算为6%)
- Sales of Pulmicort 上涨11%(按CER计算为12%)，至11.76亿美元
- Fasenra 去年11月在美国获得批准
其他疾病领域
$4,156m
产品销售额(2016年:50.67亿美元，2015年:63.4亿美元)
Highlights
- Nexium 销售额下降4%(按CER计算为3%)，至19.52亿美元
- Sales of Synagis 上涨1%(按净成本计算为1%)，至6.87亿美元
- Seroquel XR 销售额3.32亿美元，下降55%(按CER计算为55%)
- 喷雾疫苗/ Fluenz 销售额7800万美元，同比下降25%(按CER计算为28%)。
